Sera Prognostics (SERA) Q2 Loss Down 4%
Sera Prognostics (NASDAQ:SERA), a diagnostic company specializing in pregnancy risk prediction, reported Q2 2025 results on August 6, 2025. The company’s headline news was a net loss improvement and continued strategic investment toward commercial rollout, despite revenue remaining extremely modest. Revenue (GAAP) was $17,000 in Q2 2025. Net loss (GAAP) was $8.0 million in Q2 2025, improving from a GAAP net loss of $8.3 million in Q2 2024. Earnings per share (EPS) (GAAP) was ($0.16) in Q2 2025. This quarter marked careful expense management, hands-on progress in clinical milestones, and key strategic hires, with management positioning the company for future commercial expansion.
Source: Analyst estimates for the quarter provided by FactSet.
Sera Prognostics focuses on developing blood tests to assess pregnancy risk, most notably its PreTRM test. This product aims to predict the risk of premature birth, using protein biomarkers detected in blood samples taken during pregnancy. The company leverages a proprietary proteomics and bioinformatics platform, combining advanced mass spectrometry, immunoassays, and a comprehensive biobank for the discovery and validation of new pregnancy-related biomarkers.
Source Fool.com
